Alumis Inc. (ALMS) — 10-Q Filings

10-Q Filings (5)

• Alumis' Q3 Loss Widens Amid Soaring R&D, ACELYRIN Merger Boosts YTD — Nov 13, 2025 Risk: high
  Alumis Inc. (ALMS) reported a net loss of $110.75 million for the three months ended September 30, 2025, an increase from the $93.12 million net loss in the sam
• Alumis Swings to Profit on ACELYRIN Merger Gain, R&D Soars — Aug 13, 2025 Risk: high
  ALUMIS INC. (ALMS) reported a net income of $59.321 million for the three months ended June 30, 2025, a significant turnaround from a net loss of $56.508 millio
• Alumis Inc. Files Q1 2025 10-Q — May 14, 2025 Risk: low
  Alumis Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Esker Therapeutics, Inc., is in the pharmaceutical preparations industry.
• Alumis Inc. Files Q3 2024 10-Q Report — Nov 13, 2024 Risk: medium
  Alumis Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly Esker Therapeutics, Inc., is based in South San Francisco, CA. The fi
• Alumis Inc. Files Q2 2024 10-Q — Aug 13, 2024 Risk: medium
  Alumis Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Esker Therapeutics, Inc., reported financial data for its fiscal

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX